RBC Capital Reiterates Outperform Rating on Biogen (BIIB), very likely Leqembi will be approved in Europe
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $303.00 price target on Biogen (NASDAQ: BIIB).The analyst said: "Recall ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
